A Multicenter, Prospective, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of BB3 to Assess the Safety and Efficacy of BB3 in Patients Developing Acute Kidney Injury After Cardiac Surgery
Phase of Trial: Phase II
Latest Information Update: 14 Jun 2017
At a glance
- Drugs BB 3 (Primary)
- Indications Acute kidney injury
- Focus Therapeutic Use
- Acronyms GUARD
- Sponsors Angion Biomedica
- 31 Jan 2017 According to an Angion Biomedica media release, first patient has been enrolled in the study.
- 17 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Mar 2018.
- 17 Jan 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2017.